Top Story

VOYAGE 1: Guselkumab yields encouraging outcomes in plaque psoriasis

September 19, 2017

At 100 weeks, more than 80% of patients with moderate to severe plaque psoriasis showed improvement after treatment with guselkumab, according to findings presented at the 26th European Academy of Dermatology and Venereology Congress.

The data were from the 2-year, open-label follow-up of the VOYAGE 1 trial. The cohort of patients treated with guselkumab (Tremfya, Janssen), an anti-interleukin-23 monoclonal antibody, included patients who had previously been treated with adalimumab (Humira, AbbVie).

Meeting News

Adalimumab biosimilar safety, efficacy matches Humira through 51 weeks

September 18, 2017
A biosimilar of adalimumab was associated with similar safety and efficacy outcomes compared with Humira in a cohort of patients with chronic plaque psoriasis, according…
Meeting News

Baricitinib improves outcomes in patients with atopic dermatitis

September 14, 2017
Patients with moderate-to-severe atopic dermatitis experienced improvements in both clinical and patient-reported outcomes after treatment with Olumiant plus topical…
In the Journals

Pneumocystis prophylaxis may be unnecessary in autoimmune blistering diseases

September 11, 2017
One patient in a large cohort of individuals with autoimmune blistering diseases developed pneumocystis pneumonia, suggesting that routine prophylaxis of this condition…
More Headlines »